Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ilofotase alfa
- Development stage
- Phase 2
- Lead developer
- AM-Pharma
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Ilofotase alfa is a recombinant alkaline phosphatase developed by AM-Pharma for treating acute kidney injury and hypophosphatasia. It acts as an enzyme replacement therapy, dephosphorylating and detoxifying damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS), ATP, ADP, which are involved in acute inflammation and kidney damage.
- Brand names
- ilofotase alfa
- Other names
- Recombinant optimised human alkaline phosphatase
02
Targets
P2Y (P2Y receptors)ALPL (Tissue-nonspecific alkaline phosphatase)
Beyond the preview
Go deeper on ilofotase alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ilofotase alfa.